Atom Investors LP Buys Shares of 1,883,018 Fractyl Health, Inc. $GUTS

Atom Investors LP bought a new stake in shares of Fractyl Health, Inc. (NASDAQ:GUTS) during the 4th quarter, Holdings Channel reports. The firm bought 1,883,018 shares of the company’s stock, valued at approximately $4,143,000.

Several other hedge funds have also recently added to or reduced their stakes in GUTS. Jane Street Group LLC bought a new stake in Fractyl Health during the 2nd quarter valued at $31,000. FNY Investment Advisers LLC bought a new stake in Fractyl Health during the 3rd quarter valued at $31,000. Scientech Research LLC bought a new stake in Fractyl Health during the 3rd quarter valued at $49,000. Prelude Capital Management LLC bought a new stake in Fractyl Health during the 3rd quarter valued at $55,000. Finally, Arrowpoint Investment Partners Singapore Pte. Ltd. bought a new stake in Fractyl Health during the 3rd quarter valued at $56,000.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. Wall Street Zen raised Fractyl Health from a “strong sell” rating to a “hold” rating in a research note on Saturday, May 16th. HC Wainwright reissued a “buy” rating and issued a $8.00 price objective on shares of Fractyl Health in a research note on Thursday, June 4th. Canaccord Genuity Group reissued a “buy” rating and issued a $8.00 price objective on shares of Fractyl Health in a research note on Thursday, March 26th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Fractyl Health in a research note on Tuesday, May 12th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Fractyl Health currently has an average rating of “Hold” and a consensus target price of $5.40.

Fractyl Health Stock Down 8.7%

GUTS opened at $0.78 on Wednesday. Fractyl Health, Inc. has a one year low of $0.38 and a one year high of $2.45. The company has a debt-to-equity ratio of 1.41, a quick ratio of 4.28 and a current ratio of 4.28. The stock’s fifty day moving average is $0.71 and its 200-day moving average is $1.06. The company has a market capitalization of $123.11 million, a PE ratio of -0.60 and a beta of 2.34.

Fractyl Health (NASDAQ:GUTS) last posted its quarterly earnings data on Tuesday, May 12th. The company reported $0.06 EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.23. On average, equities analysts predict that Fractyl Health, Inc. will post -0.6 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Ian Sheffield bought 35,000 shares of the business’s stock in a transaction dated Wednesday, June 10th. The shares were bought at an average cost of $0.73 per share, with a total value of $25,550.00. Following the completion of the transaction, the director directly owned 35,000 shares of the company’s stock, valued at approximately $25,550. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director William Bradley bought 68,493 shares of the business’s stock in a transaction dated Wednesday, June 10th. The shares were bought at an average cost of $0.73 per share, for a total transaction of $49,999.89. Following the completion of the transaction, the director directly owned 84,622 shares of the company’s stock, valued at $61,774.06. This trade represents a 424.66% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have bought 171,493 shares of company stock worth $127,150 over the last ninety days. 8.52% of the stock is owned by insiders.

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.